Deep brain stimulation (DBS) surgery is performed as part of the treatment of various neural debilitating conditions such as Parkinson’s disease (PD), dementia, and Alzheimer’s disease. A patient fitted with a DBS device can get long-term relief from debilitating symptoms of PD. Although, some patients may require medications post-surgery, there is significant reduction in side-effects caused due to medications, owing to use of DBS devices. A DBS device is mainly placed in one of the three U.S. Food and Drug Administration (FDA) approved target sites in PD. Most commonly preferred target sites are the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN).
DBS devices are widely used in the treatment and management of diseases such as epilepsy and PD. Therefore, high prevalence of these diseases worldwide is expected to drastically increase demand for its management devices, thereby driving the global deep brain stimulation devices market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) in June 2019, epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Globally, around 50 million people suffer from epilepsy, making it one of the most common neurological diseases.
Market Dynamics
Approval and launch of novel and advanced DBS devices is expected to drive the global deep brain stimulation devices market growth over the forecast period. For instance, in January 2021, Medtronic plc, a U.S. based medical device company, announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state.DBS devices are widely used in the treatment and management of diseases such as epilepsy and PD. Therefore, high prevalence of these diseases worldwide is expected to drastically increase demand for its management devices, thereby driving the global deep brain stimulation devices market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) in June 2019, epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Globally, around 50 million people suffer from epilepsy, making it one of the most common neurological diseases.
Key features of the study:
- This report provides an in-depth analysis of the global deep brain stimulation devices market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global deep brain stimulation devices market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include, Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global deep brain stimulation devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global deep brain stimulation devices market
Detailed Segmentation:
Global Deep Brain Stimulation Device Market, By Application:
- Parkinson's Disease
- Essential Tremor
- Dystonia
- Others
Global Deep Brain Stimulation Device Market, By End User:
- Hospital & Clinics
- Ambulatory Surgical Centers
- Others
Global Deep Brain Stimulation Device Market, By Region:
- North America
- By country
- U.S.
- Canada
- Europe
- By Country
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Boston Scientific Corporation.*
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Medtronic, Inc.
- Jude Medical, Inc. (Abbott Laboratories)
- Cyberonics, Inc.
- Neuronetics
- Aleva Neurotherapeutics SA.
Table of Contents
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Deep Brain Stimulation Devices Market- Impact of Coronavirus (Covid-19) Pandemic
5. Global Deep Brain Stimulation Devices Market, By Application, 2017 - 2030, (US$ Million)
6. Global Deep Brain Stimulation Devices Market, By End User,2017 - 2030, (US$ Million)
7. Global Deep Brain Stimulation Devices Market, By Region, 2017 - 2030, (US$ Million)
8. Competitive Landscape
9. Section
Companies Mentioned
A selection of companies mentioned in this report includes:
- Boston Scientific Corporation.*
- Medtronic, Inc.
- Jude Medical, Inc. (Abbott Laboratories)
- Cyberonics, Inc.
- Neuronetics
- Aleva Neurotherapeutics SA.